Breaking News
Get 60% Off 0
🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…
CLAIM SALE
Close

Ubs (lux) Equity Sicav - Swiss Opportunity (chf) (eur) Q-acc (0P00016OMS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
200.680 -1.040    -0.52%
26/11 - Closed. Currency in EUR
Type:  Fund
Market:  Luxembourg
Issuer:  UBS Fund Management (Luxembourg) S.A.
ISIN:  LU1240788064 
Asset Class:  Equity
  • Morningstar Rating:
  • Total Assets: 51.93M
UBS Lux Equity SICAV - Swiss Opportunity CHF EUR Q 200.680 -1.040 -0.52%

0P00016OMS Holdings

 
Comprehensive information about top holdings and Key Holding Information for the UBS Lux Equity SICAV - Swiss Opportunity CHF EUR Q (0P00016OMS) fund. Our UBS Lux Equity SICAV - Swiss Opportunity CHF EUR Q portfolio information includes stock holdings, annual turnover, top 10 holdings, sector and asset allocation.

Asset Allocation

Create Alert
Add to Watchlist
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Name  Net %  Long %  Short %
Cash 0.670 0.860 0.190
Stocks 99.330 99.330 0.000

 Style Box

Value & Growth Measures

Ratios Value Category Average
P/E Ratio 16.478 18.235
Price to Book 2.926 3.340
Price to Sales 1.752 2.111
Price to Cash Flow 14.499 14.205
Dividend Yield 3.179 2.899
5 Years Earnings Growth 8.190 11.496

Sector Allocation

Name  Net % Category Average
Healthcare 33.110 30.340
Financial Services 27.430 20.164
Consumer Defensive 13.260 13.621
Industrials 13.130 16.302
Technology 4.890 3.652
Consumer Cyclical 4.390 5.279
Communication Services 2.730 2.741
Basic Materials 1.060 8.485

Region Allocation

  • Europe Developed
  • Developed Markets

Top Holdings

Number of long holdings: 47

Number of short holdings: 5

Name ISIN Weight % Last Change %
  Novartis CH0012005267 10.04 92.75 +0.89%
  Roche Holding Participation CH0012032048 9.94 252.50 +0.44%
  Nestle CH0038863350 9.33 76.36 +0.69%
  Zurich Insurance Group CH0011075394 7.43 552.60 -0.07%
  ABB CH0012221716 4.91 49.02 -1.05%
  UBS Group CH0244767585 4.70 27.67 -0.32%
  Swiss Re CH0126881561 4.66 128.70 -0.08%
  Lonza Group CH0013841017 4.13 517.00 -2.64%
  Alcon CH0432492467 3.76 78.00 +0.49%
  Swiss Life Holding CH0014852781 3.64 717.80 -0.22%

Top Equity Funds by UBS Fund Management (Luxembourg) S.A.

  Name Rating Total Assets YTD% 3Y% 10Y%
  LU1923635863 2.87B 11.18 -8.80 -
  LU2000522420 2.87B 7.05 -13.84 -
  UBSLuxEqSICAV USA Growth H FAcc 2.88B 22.48 3.78 12.51
  LU0508198768 2.88B 21.94 3.24 11.94
  LU0511785726 2.88B 20.90 2.19 10.80
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

0P00016OMS Comments

Write your thoughts about Ubs (lux) Equity Sicav - Swiss Opportunity (chf) (eur) Q-acc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email